Ars Pharmaceuticals Inc (SPRY) - News Archive

: Anaphylaxis, a severe and life-threatening allergic reaction, requires immediate intervention with epinephrine to prevent severe progression. Traditionally delivered via auto-injectors, epinephrine administration is n...

Neffy Nasal Spray: A New Era in Pediatric Allergy Treatment Amid Financial Challenges for ARS PharmaceuticalsIn a significant advancement for pediatric medicine, ARS Pharmaceuticals recently received FDA approval for Ne...

The biopharmaceutical landscape is characterized by innovation, competition, and financial accountability. ARS Pharmaceuticals Inc. has recently gained attention with the announcement of its epinephrine nasal spray, nef...

: In a landmark development within the pharmaceutical landscape, ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray), marking its position as the first and only needle-free treatment sp...

In an unprecedented advancement in the realm of pediatric healthcare, ARS Pharmaceuticals has formally submitted a supplemental New Drug Application (sNDA) to the esteemed Food and Drug Administration (FDA) in regard to...

ARS Pharmaceuticals Innovates Allergy Management with Needle-Free Epinephrine Nasal Spray SummaryARS Pharmaceuticals, a biopharmaceutical firm committed to advancing allergen protection for at-risk populations, has take...

The Innovative Breakthrough of neffy: Redefining Epinephrine Delivery for Anaphylaxis The rapid onset of anaphylaxis is a potentially life-threatening reaction in susceptible individuals, necessitating immediate adminis...

In an industry where innovation progresses at every turn, ARS Pharmaceuticals has emerged as a significant player with its revolutionary product, EURneffy. This adrenaline nasal spray, recently recommended for approval...

:This article delves into the significant events surrounding ARS Pharmaceuticals efforts to market their revolutionary product, neffy, an epinephrine nasal spray developed for the potential treatment of severe allergic...

ARS Pharmaceuticals, a biopharmaceutical company dedicated to providing solutions for severe allergic reactions, has recently submitted its response to the U.S. Food and Drug Administration (FDA) regarding its New Drug...

Chronic spontaneous urticaria is a distressing skin disorder characterized by recurring episodes of itchy hives and angioedema. Unfortunately, a significant number of patients with this condition do not respond adequate...

This article aims to present the findings of a repeat dosing study on neffy (Epinephrine Nasal Spray) conducted under nasal allergen challenge conditions. The study results highlight the pharmacokinetic and pharmacodyna...

Revolutionary Epinephrine Nasal Spray to Be Showcased at Prestigious AAAAI Annual MeetingSAN DIEGO, Feb. 05, 2024 - ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a pioneering biopharmaceutical company committed to providing...